Page 1

Title: Parkinsons Disease Therapeutics in Major Developed Markets to 2021: Develop Severe Symptoms and Complications that Significantly Impact upon the Patient's Quality of Life, Pipeline Shifts Towards Disease-Modifying Therapies and Growth Driven by Long-Acting Symptomatic Treatments, Short Summary Parkinsons Disease Therapeutics in Major Developed Markets to 2021: Early Pipeline Shifts Towards Disease-Modifying Therapies, while Short Term Growth Driven by Long-Acting Symptomatic Treatments Size and Share Published in 2016-02-11 Available for US$ 4995 at Description Parkinson's Disease (PD) is a progressive, chronic neurodegenerative condition, which is currently incurable. It is associated with old age, and characterized by the loss of neurons in the substantia nigra region of the brain. The global Parkinson's Disease (PD) prevalence was estimated at 16.1 million in 2011, and after Alzheimer's disease it is the second most common neurodegenerative disease worldwide. Parkinson's Disease (PD) is a progressive disease and, although not fatal, it can develop severe symptoms and complications that significantly impact upon the patient's quality of life. Symptoms for each stage can be categorized into early, moderate and advanced stages. Major motor symptoms of Parkinson's Disease (PD) include tremors and difficulty walking. Parkinson's Disease (PD) also gives rise to non-motor symptoms, such as dementia, depression, hallucinations and loss of taste and smell. There are several different drug classes available to relieve Parkinson's Disease (PD) symptoms. The aim is for treatments to increase dopamine levels, which is substantially diminished in brains affected by Parkinson's Disease (PD). The most common therapies include levodopa, dopamine agonists and Monoamine Oxidase-B (MAO-B) inhibitors, with the choice of therapies dependent on patient symptoms and lifestyle. As the disease develops, the medication will need to be taken more strictly, due to the effect of drugs wearing off (known as offtime), which causes symptoms to return before the next dose. With the current marketed drugs focusing primarily on symptomatic relief, Parkinson's Disease (PD) remains incurable, with a huge unmet need for disease-modifying therapies. However, due to the lack of clearly established clinical trial methodologies, replication of the benefits demonstrated by neuroprotective agents in the laboratory to human trials has proved challenging. More importantly, due to an incomplete understanding of the underlying mechanisms that cause the disease, a viable therapeutic target to halt or slow disease progression is currently not in scope, which limits the effectiveness of current product development programs.

Get a Sample Copy of the Report: type=S&repid=668356


A brief introduction to Parkinson’s Disease (PD), including pathogenesis, disease staging, diagnosis and treatment algorithms Comprehensive analysis of the drugs available for the treatment of PD, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy Comprehensive analysis of the pipeline for Parkinson’s Disease (PD) therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period, on the basis of Phase distribution, molecule type and molecular target Additional thorough analysis of pipeline drug clinical trials by Phase, molecule type, trial size, trial duration, and program failure rate for each molecule type and mechanism of action Multi-scenario market forecast data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain Discussion of the drivers of and barriers to market growth Discussion of the licensing and co-development deals landscape in Parkinson’s Disease (PD), by stage of development, molecule type and mechanism of action, as well as analysis of both licensing and co-development deals by year, and network maps of licensing and codevelopment deals

Reasons to buy Understand the different levels of Parkinson’s Disease (PD) therapy from early-stage to advanced Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent Observe the trends in clinical trial duration and size among clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or forthcoming developmental programs for Parkinson’s Disease (PD) therapeutics Observe the trends in clinical trial duration and size among clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for Parkinson’s Disease (PD) therapeutics Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the Parkinson’s Disease (PD) therapeutics market

Inquiry on this report: type=E&repid=668356

Table of Content 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 7

2 Introduction 9 2.1 Disease Introduction 9 2.2 Symptoms 9 2.3 Etiology 10 2.3.1 Genetic Factors 10 2.3.2 Environmental Factors 11 2.3.3 Aging 11 2.4 Pathophysiology 12 2.5 Epidemiology 13 2.6 Disease Stages 14 2.7 Co-morbidities and Complications 15 2.8 Diagnosis 15 2.9 Assessment of Disease Severity 16 2.9.1 Hoehn and Yahr scale 16 2.9.2 Unified Parkinson’s Disease Rating Scale 16 2.10 Treatment 17 2.10.1 Pharmacological Therapies 18 2.10.2 Non-pharmacological Treatments 20 2.11 Treatment Algorithm 21 2.11.1 Early Parkinson’s Disease 21 2.11.2 Advanced Parkinson’s Disease 22

3 Marketed Products 25 3.1 Overview 25 3.1.1 Dopamine Replacement Therapies 25 3.1.2 MAO-B Inhibitors 28 3.1.3 Dopamine Agonists 30

3.1.4 COMT Inhibitors 35 3.1.5 Other Drugs Targeting Non-motor Symptoms of PD 39 3.2 Comparative Efficacy and Safety 40

Browse All Therapeutic Area Market Research Reports at:

About ResearchMoz ResearchMoz   is   the   world’s   fastest   growing   collection   of   market   research reports worldwide. Our database is composed of current market studies from over   100   featured   publishers   worldwide.   Our   market   research   databases integrate statistics with analysis from global, regional, country and company perspectives.  Contact Us: ResearchMoz Mr. Nachiket Ghumare, +1-518-621-2074 USA-Canada Toll Free: 866-997-4948

Parkinsons disease therapeutics in major developed markets to 2021  
Read more
Read more
Similar to
Popular now
Just for you